PT79012A - Enhancement of pharmaceutical activity - Google Patents

Enhancement of pharmaceutical activity

Info

Publication number
PT79012A
PT79012A PT79012A PT7901284A PT79012A PT 79012 A PT79012 A PT 79012A PT 79012 A PT79012 A PT 79012A PT 7901284 A PT7901284 A PT 7901284A PT 79012 A PT79012 A PT 79012A
Authority
PT
Portugal
Prior art keywords
enhancement
pharmaceutical activity
pharmaceutical
activity
Prior art date
Application number
PT79012A
Other languages
English (en)
Original Assignee
Liposome Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Corp filed Critical Liposome Corp
Publication of PT79012A publication Critical patent/PT79012A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT79012A 1983-08-01 1984-08-01 Enhancement of pharmaceutical activity PT79012A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51891283A 1983-08-01 1983-08-01
US06/633,481 US5000958A (en) 1983-08-01 1984-07-26 Enhancement of pharmaceutical activity

Publications (1)

Publication Number Publication Date
PT79012A true PT79012A (en) 1984-09-01

Family

ID=27059635

Family Applications (1)

Application Number Title Priority Date Filing Date
PT79012A PT79012A (en) 1983-08-01 1984-08-01 Enhancement of pharmaceutical activity

Country Status (11)

Country Link
US (1) US5000958A (pt)
EP (1) EP0153364B1 (pt)
AU (1) AU3219484A (pt)
CA (1) CA1237671A (pt)
DE (1) DE3483322D1 (pt)
ES (1) ES8603264A1 (pt)
IL (1) IL72545A (pt)
IT (1) IT1179029B (pt)
PT (1) PT79012A (pt)
SG (1) SG18592G (pt)
WO (1) WO1985000515A1 (pt)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU588299B2 (en) * 1985-04-08 1989-09-14 Rafa Laboratories Ltd. Artificial microcompartmentalization
US5409704A (en) * 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
DE3689769T2 (de) * 1985-07-05 1994-07-21 Liposome Co Inc Multilamellare liposome mit verbesserter einschliessungswirkung.
FR2628317B1 (fr) * 1988-03-09 1991-11-08 Lvmh Rech Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un extrait de scutellaria, ou au moins un flavonoide tel que baicaleine ou baicaline et composition cosmetique ou pharmaceutique, notamment dermatologique, a activite anti-allergique, anti-inflammatoire ou anti-vieillissement, l'incorporant
MX9203504A (es) * 1988-04-20 1992-07-01 Liposome Co Inc Complejo agente: lipido activo de alta proporcion.
EP0414806B1 (en) * 1988-05-20 1994-07-20 The Liposome Company, Inc. High ratio active agent:lipid complex
US5269979A (en) * 1988-06-08 1993-12-14 Fountain Pharmaceuticals, Inc. Method for making solvent dilution microcarriers
CA1340241C (en) * 1988-06-08 1998-12-15 Fountain Pharmaceuticals, Inc. Method for marking solvent dilution microcarriers
US4952405A (en) * 1988-10-20 1990-08-28 Liposome Technology, Inc. Method of treating M. avium infection
ATE147633T1 (de) * 1988-10-27 1997-02-15 Univ Minnesota Immunhilfsmittel aus liposome enthaltend lymphokin il -2
AU5666090A (en) * 1989-05-25 1990-12-18 Technology Unlimited Incorporated Insect repellant
NZ237464A (en) * 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5264220A (en) * 1991-11-12 1993-11-23 Long David M Jr Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents
DE69227042T3 (de) * 1991-12-31 2006-07-27 Zymogenetics, Inc., Seattle Verfahren und zusammensetzungen zur verminderung von blutverlust
EP0585514B1 (en) * 1992-01-09 1998-10-07 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d., Ljubljana Animal feed and an additive thereto or to drinking water containing an antibiotic mixture of gentamicin with lincomycin or clindamycin
US5344822A (en) * 1992-08-12 1994-09-06 The Rogosin Institute Methods useful in endotoxin prophylaxis and therapy
US5674855A (en) * 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
AU3244393A (en) * 1992-12-02 1994-06-22 Vestar, Inc. Antibiotic formulation and process
US5958449A (en) 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
US5759571A (en) * 1993-05-11 1998-06-02 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for drug resistant infections
US5478819A (en) * 1993-06-23 1995-12-26 Simo Tarpila Phospholipid composition and use thereof
WO1995008344A1 (en) * 1993-09-22 1995-03-30 Xoma Corporation Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic
EP0664117A1 (de) * 1994-01-25 1995-07-26 F. Hoffmann-La Roche Ag Liposomenlösungen
US20020028215A1 (en) 1999-08-09 2002-03-07 Jagath L. Kadurugamuwa Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6183774B1 (en) 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US6071535A (en) * 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US5874105A (en) * 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
CN1624126A (zh) 1996-05-08 2005-06-08 拜奥根有限公司 刺激神经和肾生长的RET配体（RetL）
AU4151697A (en) * 1996-08-14 1998-03-06 Vanderbilt University Compositions of antichlamydial agents for the diagnosis and management of infection caused by (chlamydia)
US5935572A (en) * 1997-01-10 1999-08-10 Collaborative Laboratories, Inc. Composition containing protease separate from glycosidase for removing nits in treating lice infestation
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
AU2002334761A1 (en) * 2001-10-01 2003-04-14 The Board Of Trustees Of The University Of Illinois Methods of treating drug-resistant bacterial infections
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
EP1476194A4 (en) * 2002-02-19 2005-05-18 Eden Research Plc COMPOSITIONS AND METHOD FOR PRESERVING FOODSTUFFS
EP1487413A4 (en) * 2002-03-05 2010-11-10 Transave Inc INHALATION SYSTEM FOR THE TREATMENT OF INTRACELLULAR INFECTIONS
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
AU2003304204B2 (en) * 2002-10-29 2009-12-24 Insmed Incorporated Sustained release of antiinfectives
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US6846966B2 (en) * 2002-11-26 2005-01-25 Exxonmobil Chemical Patents Inc. Method and apparatus for treating oxygenate-containing feeds and their use in conversion of oxygenates to olefins
FR2852513A1 (fr) * 2003-03-17 2004-09-24 Groupe Lepine Combinaison d'antibiotiques gentamicine/clindamycine et ses applications aux ciments orthopediques curatifs
US7666846B2 (en) 2003-04-02 2010-02-23 The United States Of America As Represented By The Department Of Health And Human Services Cholesterol-containing compounds and their use as immunogens against Borrelia burgdorferi
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
WO2005095450A2 (en) 2004-03-30 2005-10-13 Nsgene A/S Therapeutic use of a growth factor, nsg33
US20090136552A1 (en) * 2004-07-30 2009-05-28 Mette Gronborg Growth factors nsg28, nsg30, and nsg32
CA2581133A1 (en) * 2004-09-20 2006-03-30 British Columbia Cancer Agency Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin
US20110020434A1 (en) * 2005-09-02 2011-01-27 O'halloran Thomas V Nanoparticle arsenic-platinum compositions
DE102005063375A1 (de) * 2005-09-15 2007-04-19 Schülke & Mayr GmbH Antimikrobielle Zubereitungen mit einem Gehalt an Octenidindihydrochlorid verkapselt in Liposomen
CN101355876B (zh) 2005-11-09 2012-09-05 康宾纳特克斯公司 一种适用于眼部给药的组合物
AU2006322076C1 (en) 2005-12-08 2013-11-14 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
WO2008137717A1 (en) * 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US8470762B2 (en) * 2007-05-31 2013-06-25 Colgate-Palmolive Company Fabric softening compositions comprising polymeric materials
EP2244698A1 (en) * 2008-02-25 2010-11-03 The University Of North Carolina At Charlotte Office Of Technology Transfer Biodegradable therapeutic nanoparticles containing an antimicrobial agent
RU2547441C2 (ru) 2008-03-06 2015-04-10 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы в качестве противовоспалительных агентов
EP2451944A4 (en) 2009-07-10 2012-11-28 Harvard College Permanently loaded soda and calcium channel blockers as anti-inflammatory agents
ES2677352T3 (es) 2009-12-18 2018-08-01 Achelios Therapeutics, Inc. Métodos y composiciones para tratar y prevenir las cefaleas autonómicas trigeminales, la migraña y las afecciones vasculares
WO2011094450A1 (en) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Boron-containing small molecules
CN103339149B (zh) 2010-06-14 2016-02-03 H.隆德贝克有限公司 SorLA和GDNF-家族配体受体之间的相互作用的调节
US9212201B2 (en) * 2010-07-23 2015-12-15 Acea Biotech, Inc. Antifungal and antiparasitic polyene macrolides
EP2621512B1 (en) 2010-10-01 2016-04-06 NsGene A/S Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
AU2013266400B2 (en) 2012-05-21 2017-06-22 Insmed Incorporated Systems for treating pulmonary infections
RU2018135921A (ru) 2012-11-29 2019-02-05 Инсмед Инкорпорейтед Стабилизированные составы ванкомицина
LT3466432T (lt) 2014-05-15 2020-12-28 Insmed Incorporated Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
WO2015188140A1 (en) 2014-06-06 2015-12-10 The Curators Of The University Of Missouri Enhancement of antibiotic efficacy
WO2016089893A1 (en) 2014-12-01 2016-06-09 Achelios Therapeutics Inc. Methods and compositions for treating migraine and conditions associated with pain
RU2018107695A (ru) 2015-08-03 2019-09-05 Президент Энд Феллоуз Оф Гарвард Колледж Заряженные блокаторы ионных каналов и способы их применения
JP2019532027A (ja) 2016-08-17 2019-11-07 ソルスティス バイオロジクス，リミティッド ポリヌクレオチド構築物
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS
US10828287B2 (en) 2019-03-11 2020-11-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
MA55318A (fr) 2019-03-11 2022-01-19 Nocion Therapeutics Inc Bloqueurs de canaux ioniques chargés et procédés d'utilisation
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11377422B2 (en) 2019-03-11 2022-07-05 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
JP2022527731A (ja) 2019-03-11 2022-06-06 ノシオン セラピューティクス，インコーポレイテッド エステル置換イオンチャンネル遮断薬および使用方法
IL292505A (en) 2019-11-06 2022-06-01 Nocion Therapeutics Inc Charged ion channel blockers and methods of use
EP4054586A4 (en) 2019-11-06 2023-11-22 Nocion Therapeutics, Inc. CHARGED ION CHANNEL BLOCKERS AND METHODS OF USE
IL295950A (en) 2020-03-11 2022-10-01 Nocion Therapeutics Inc Charged ion channel blockers and methods of use
CN117940149A (zh) 2021-05-06 2024-04-26 霍巴治疗公司 化疗诱导的神经性疼痛的预防和治疗
AU2022405685A1 (en) 2021-12-10 2024-07-11 Hoba Therapeutics Aps Treatment of nociceptive pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5231981A (en) * 1975-08-18 1977-03-10 Takeda Chem Ind Ltd Microcapsule preparation method
US4356167A (en) * 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4328222A (en) * 1978-11-21 1982-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions for parenteral or local administration
US4241046A (en) * 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4588578A (en) * 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase

Also Published As

Publication number Publication date
IL72545A (en) 1987-11-30
ES542147A0 (es) 1985-12-16
US5000958A (en) 1991-03-19
IT8467767A1 (it) 1986-02-01
ES8603264A1 (es) 1985-12-16
IT8467767A0 (it) 1984-08-01
AU3219484A (en) 1985-03-04
EP0153364A1 (en) 1985-09-04
EP0153364A4 (en) 1987-03-03
WO1985000515A1 (en) 1985-02-14
IT1179029B (it) 1987-09-16
SG18592G (en) 1992-04-16
EP0153364B1 (en) 1990-09-26
CA1237671A (en) 1988-06-07
DE3483322D1 (de) 1990-10-31

Similar Documents

Publication Publication Date Title
PT79012A (en) Enhancement of pharmaceutical activity
DE3372929D1 (en) Treatment of catalysts
GB8430083D0 (en) Preparation of controlled pharmaceuticals
GB8415139D0 (en) Modification of polyolycolic structural elements
GB8320832D0 (en) Determination of enzyme activity
GB8519041D0 (en) Immobilization of elements of fission products
EP0130007A3 (en) Preparation of amino-polyols
IL73023A0 (en) Preparation of 2-chloro-benzoxazoles
GB8521996D0 (en) Treatment of structure
ZA845997B (en) Pharmaceutical compositions with antibiotic-immunostimulating activity
ZA845950B (en) Enhancement of pharmaceutical activity
IL73787A (en) Preparation of 2-haloresorcinols
GB8401278D0 (en) Preparation of cyanotetrachlorobenzenes
EP0149832A3 (en) Preparation of thiolcarbamates
GB2139619B (en) Preparation of azinomethyl-rifamycins
GB8323068D0 (en) Treatment of chilblains
HUT36680A (en) Sinergizated herbicid preparatives consisting of tiolcarbamates
ZA851858B (en) Treatment of zircon
GB8409380D0 (en) Preparation of 3-benzothienylglycines
IL75967A0 (en) Preparation of n-thienylchloroacetamides
GB8404108D0 (en) Preparation of copperchloride
IE831423L (en) Sulphoxids of thioformamide
GB8301424D0 (en) Assemblies of shapes
DE3475067D1 (en) Preparation of mexamine
AU87691S (en) Set of bedlinen